Skip to main content

Table 1 Characteristics of HIV infected patients using ART with gender category at Hawassa, Southern Ethiopia

From: Influences of gender in metabolic syndrome and its components among people living with HIV virus using antiretroviral treatment in Hawassa, southern Ethiopia

Variables

Males

(No = 68)

Females

(No = 117)

Age (years), median (IQR)

35 (28.2–40.0)

30 (25–35)

 <25

8 (11.8)

32 (27.4)

 26–35

27 (39.7)

61 (52.1)

 36–45

26 (38.2)

21 (17.9)

 ≥46

7 (10.3)

3 (2.6)

Marital status

 Single

 15 (22.0)

24 (20.5)

 Married

38 (55.9)

54 (46.1)

 Divorced

7 (10.3)

12 (10.2)

 Widowed

8 (11.7)

27 (23.1)

Work status

 Unemployed

6 (8.8)

14 (11.9)

 Government

16 (23.5)

14 (11.9)

 Private

43 (63.2)

53 (25.6)

 Student

3 (4.4)

6 (5.1)

 A housewife

30 (29.0)

Physical exercise

 Sedentary

25 (36.7)

57 (48.7)

 Moderate

38 (55.9)

59 (50.4)

 Vigorous

5 (7.3)

1 (0.8)

BMI (kg/m2)

22.2 (3.2)

22.2 (3.7)

 <18.5

4 (5.9)

21 (17.9)

 18.5–24.9

50 (73.5)

75 (64.1)

 ≥25

14 (20.6)

21 (17.9)

CD4, cells/µl, median (IQR)

340 (200–486)

433 (326–572)

 <200

14 (20.6)

10 (8.5)

 200–400

25 (36.7)

32 (27.4)

 ≥400

29 (42.7)

75 (64.1)

WHO clinical stage

 I

21 (30.9)

37 (31.6)

 II

13 (19.1)

21 (17.9)

 III

29 (42.6)

48 (41.0)

 IV

5 (7.3)

11 (9.4)

NRTIs

 AZT

21 (30.9)

52 (44.4)

 TDF

27 (39.7)

32 (27.3)

 d4T

20 (29.4)

33 (28.2)

NNRTIs

 EFV

46 (67.6)

63 (53.8)

 NVP

22 (32.3)

54 (46.1)

 ART duration (months)

41.4 (19.4)

45.1 (21.5)

  1. Values are the number (percent) for variables unless otherwise indicated
  2. WHO world health organization, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non nucleoside reverse transcriptase inhibitor, BMI body mass index, ART antiretroviral therapy, AZT Zidovudine, EFV Efavirenz, NVP Nevirapine, IQR interquartile range